Loading...
XSTO
ALIF B
Market cap13bUSD
Sep 17, Last price  
163.20
1D
0.74%
1Q
4.88%
Jan 2017
397.88%
IPO
587.04%
Name

AddLife AB

Chart & performance

D1W1MN
XSTO:ALIF B chart
P/E
P/S
EPS
4.60
Div yield, %
0.46%
Shrs. gr., 5y
1.58%
Rev. gr., 5y
14.64%
Revenues
10.44b
+1.52%
906,500,000983,500,0001,722,600,0001,562,400,0001,938,300,0002,333,300,0002,481,600,0003,479,400,0005,273,300,0007,992,600,0009,084,000,0009,685,000,00010,286,000,00010,442,000,000
Net income
560m
+122.22%
73,800,00078,000,000102,000,00077,800,000111,800,000120,300,000129,300,000140,600,000517,800,000719,000,000480,000,000190,000,000252,000,000560,000,000
CFO
1.39b
+27.12%
118,600,00091,600,000120,400,000117,700,000132,900,000208,000,000177,500,000400,400,000950,100,0001,010,200,000909,000,000773,000,0001,095,000,0001,392,000,000
Dividend
May 07, 20261.5 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AddLife AB (publ), a company established in 1906 and headquartered in Stockholm, Sweden, specializes in delivering cutting-edge equipment, medical apparatus, and chemical reagents. Its primary clientele includes the healthcare sector, academic and research organizations (such as colleges and universities), and key players within the food and pharmaceutical industries. The firm's operations are divided into two distinct divisions: Labtech and Medtech. The Labtech segment provides a comprehensive array of products, integrated solutions, and expert services, focusing on diagnostics, biomedical research, and general laboratory requirements. This encompasses specialized instruments for areas like haematology, pathology, immediate diagnostic testing (point-of-care), cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, along with consumables and advanced analytical machinery. This division further offers vital support, maintenance, consultancy, and educational programs. Conversely, the Medtech segment concentrates on supplying a wide range of medical devices tailored for critical applications such as surgical procedures, respiratory support, intensive care, wound management, and enteral nutrition. It also develops products for fall prevention, welfare technology, and ear, nose, and throat conditions, in addition to offering specific assistive devices for bathrooms and specialized aids for children with disabilities. AddLife maintains a broad international presence, conducting business in its home country of Sweden, across the Nordics (Finland, Denmark, Norway), the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, other parts of Europe, and globally.

Related entities

Subsidiaries (15)
AddLife Development AB
Bergman Labora AB
Bio-Connect B.V.
Biolin Scientific AB
BioNordika (Sweden) AB
BIONORDIKA DENMARK A/S
FISCHER MEDICAL ApS
HEPRO AS
HOLM & HALBY A/S
Mediplast AB
Svan Care AB
TRIOLAB A/S
Triolab Aktiebolag
TRIOLAB AS
Triolab Oy

Key people

Independent Director · since 2015
IPO date
Mar 16, 2015
Employees
2,296
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Box 3145
Stockholm, AB 103 62
SE
Previous name
Addtech Holding AB
Previous name
Goldcup 9918 AB

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT